Evident Vascular wins FDA clearance for AI-powered IVUS imaging platform
What's the deal? Evident VascularDealroom has a profile for this one. Try Dealroom → has received FDA 510(k) clearance for its Guidance System and peripheral imaging catheters, the company announced November 4, 2026. The platform is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions.
What's the endgame? Evident is building an intravascular ultrasound (IVUS) system that pairs high-fidelity imaging with purpose-built AI and streamlined workflow. Its catheters are flushless and plug-and-play, and the system adds hands-free voice control and a custom user interface designed to speed up procedures.
How does it work? The platform combines custom imaging electronics with real-time processing on NVIDIADealroom has a profile for this one. Try Dealroom → accelerated computing; Evident is a member of the NVIDIA Inception program for startups. At its core is the company's proprietary DFC technology, which provides dynamic frequency control to optimise imaging across vessel sizes and depths.
Why it matters: Conventional IVUS imaging is often judged by resolution and ultrasound centre frequency alone. Evident takes a whole-system approach, integrating broad frequency bandwidth, transducer design, and advanced signal processing.
"The vessel-edge clarity and consistency across the field of view are remarkable," said Eric A. Secemsky, director of vascular intervention at Beth Israel Deaconess Medical CenterDealroom has a profile for this one. Try Dealroom →.
What's next? Evident intends to expand the platform's AI capabilities as clinical data grows, with new features aimed at enhancing imaging and workflow. The clearance sets up further FDA submissions tied to the company's longer-term goals.
"This clearance establishes an important foundation for further FDA submissions to enable that long-term vision," said Justin Klein, managing partner at Vensana CapitalDealroom has a profile for this one. Try Dealroom → and a founder and board director of Evident Vascular.
The signal: Evident is positioning AI at the point of care in vascular intervention, betting that a continuously growing evidence base will push IVUS from imaging toward precision therapy guidance.
Read more: business.theantlersamerican.com
Image credit: Evident Vascular
